{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:54:57Z","timestamp":1792173297156,"version":"4.4.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2009,8,4]],"date-time":"2009-08-04T00:00:00Z","timestamp":1249344000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1038\/nrclinonc.2009.112","type":"journal-article","created":{"date-parts":[[2009,8,4]],"date-time":"2009-08-04T08:22:48Z","timestamp":1249374168000},"page":"535-543","source":"Crossref","is-referenced-by-count":112,"title":["Imatinib and beyond\u2014exploring the full potential of targeted therapy for CML"],"prefix":"10.1038","volume":"6","author":[{"given":"Alfonso","family":"Quint\u00e1s-Cardama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,8,4]]},"reference":[{"key":"BFnrclinonc2009112_CR1","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker, B. J. et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408\u20132417 (2006).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2009112_CR2","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1182\/blood-2008-05-158535","volume":"112","author":"SG O'Brien","year":"2008","unstructured":"O'Brien, S. G. et al. International Randomized Study of Interferon Versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM) [abstract]. Blood 112, 186 (2008).","journal-title":"Blood"},{"key":"BFnrclinonc2009112_CR3","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1056\/NEJMoa030513","volume":"349","author":"TP Hughes","year":"2003","unstructured":"Hughes, T. P. et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 349, 1423\u20131432 (2003).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2009112_CR4","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-04-2139","volume":"11","author":"J Cortes","year":"2005","unstructured":"Cortes, J. et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin. Cancer Res. 11, 3425\u20133432 (2005).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc2009112_CR5","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","volume":"113","author":"A Quintas-Cardama","year":"2009","unstructured":"Quintas-Cardama, A. & Cortes, J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 113, 1619\u20131630 (2009).","journal-title":"Blood"},{"key":"BFnrclinonc2009112_CR6","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker, B. J. et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344, 1038\u20131042 (2001).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2009112_CR7","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/blood.V112.11.334.334","volume":"11","author":"T Hughes","year":"2008","unstructured":"Hughes, T. et al. Reduction of BCR-ABL transcript levels at 6, 12, and 18 months (mo) correlates with long-term outcomes on imatinib (IM) at 72 mo: An analysis from the international randomized study of interferon versus STI571 (IRIS) in patients (pts) with chronic phase chronic myeloid leukemia (CML-CP) [abstract]. Blood 11, 334 (2008).","journal-title":"Blood"},{"key":"BFnrclinonc2009112_CR8","doi-asserted-by":"publisher","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","volume":"26","author":"H de Lavallade","year":"2008","unstructured":"de Lavallade, H. et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J. Clin. Oncol. 26, 3358\u20133363 (2008).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2009112_CR9","doi-asserted-by":"publisher","first-page":"6136","DOI":"10.1158\/1078-0432.CCR-07-1112","volume":"13","author":"RD Press","year":"2007","unstructured":"Press, R. D. et al. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clin. Cancer Res. 13, 6136\u20136143 (2007).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc2009112_CR10","doi-asserted-by":"publisher","first-page":"7080","DOI":"10.1158\/1078-0432.CCR-07-0844","volume":"13","author":"S Branford","year":"2007","unstructured":"Branford, S. et al. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin. Cancer Res. 13, 7080\u20137085 (2007).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc2009112_CR11","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1200\/JCO.2005.03.2011","volume":"24","author":"I Iacobucci","year":"2006","unstructured":"Iacobucci, I. et al. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. J. Clin. Oncol. 24, 454\u2013459 (2006).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2009112_CR12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1182\/blood.V110.11.27.27","volume":"110","author":"F Guilhot","year":"2007","unstructured":"Guilhot, F. et al. Time to complete cytogenetic response (CCyR) does not affect long-term outcomes for patients on imatinib therapy [abstract]. Blood 110, 27 (2007).","journal-title":"Blood"},{"key":"BFnrclinonc2009112_CR13","first-page":"1557","volume":"357","author":"A Quintas-Cardama","year":"2007","unstructured":"Quintas-Cardama, A., Kantarjian, H. & Cortes, J. Tyrosine kinase inhibitors for chronic myelogenous leukemia. N. Engl. J. Med. 357, 1557 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2009112_CR14","doi-asserted-by":"publisher","first-page":"6315","DOI":"10.1182\/blood-2008-07-166694","volume":"113","author":"A Quintas-Cardama","year":"2009","unstructured":"Quintas-Cardama, A. et al. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myelogenous leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 113, 6315\u20136321 (2009).","journal-title":"Blood"},{"key":"BFnrclinonc2009112_CR15","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1182\/blood-2003-11-3800","volume":"103","author":"H Kantarjian","year":"2004","unstructured":"Kantarjian, H. et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 103, 2873\u20132878 (2004).","journal-title":"Blood"},{"key":"BFnrclinonc2009112_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1182\/blood-2003-01-0025","volume":"102","author":"J Cortes","year":"2003","unstructured":"Cortes, J. et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood 102, 83\u201386 (2003).","journal-title":"Blood"},{"key":"BFnrclinonc2009112_CR17","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1182\/blood-2008-06-161737","volume":"112","author":"TP Hughes","year":"2008","unstructured":"Hughes, T. P. et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg\/day of imatinib as initial therapy. Blood 112, 3965\u20133973 (2008).","journal-title":"Blood"},{"key":"BFnrclinonc2009112_CR18","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","volume":"111","author":"RA Larson","year":"2008","unstructured":"Larson, R. A. et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111, 4022\u20134028 (2008).","journal-title":"Blood"},{"key":"BFnrclinonc2009112_CR19","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","volume":"109","author":"S Picard","year":"2007","unstructured":"Picard, S. et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109, 3496\u20133499 (2007).","journal-title":"Blood"},{"key":"BFnrclinonc2009112_CR20","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1182\/blood-2008-04-153122","volume":"112","author":"F Guilhot","year":"2008","unstructured":"Guilhot, F. et al. Imatinib (IM) pharmacokinetic (PK) exposure and its correlation with clinical outcome in patients with chronic-phase chronic myeloid leukemia (CML-CP) for 400 mg and 800 mg daily doses (Tyrosine Kinase Dose Optimization Study [TOPS]) [abstract]. Blood 112, 447 (2008).","journal-title":"Blood"},{"key":"BFnrclinonc2009112_CR21","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1182\/blood.V112.11.4255.4255","volume":"112","author":"P Ault","year":"2008","unstructured":"Ault, P. et al. Clinical use of imatinib plasma levels in patients with chronic myeloid leukemia (CML) [abstract]. Blood 112, 4255 (2008).","journal-title":"Blood"},{"key":"BFnrclinonc2009112_CR22","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1182\/blood.V112.11.335.335","volume":"112","author":"J Cortes","year":"2008","unstructured":"Cortes, J. et al. A phase III, randomized, open-label study of 400 mg versus 800 mg of imatinib mesylate (IM) in patients (pts) with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP) using molecular endpoints: 1-year results of TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) study [abstract]. Blood 112, 335 (2008).","journal-title":"Blood"},{"key":"BFnrclinonc2009112_CR23","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1182\/blood.V112.11.185.185","volume":"112","author":"M Baccarani","year":"2008","unstructured":"Baccarani, M. et al. Cytogenetic and molecular response to imatinib in high risk (Sokal) chronic myeloid leukemia (CML): results of an European Leukemianet prospective study comparing 400 mg and 800 mg front-line [abstract]. Blood 112, 185 (2008).","journal-title":"Blood"},{"key":"BFnrclinonc2009112_CR24","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1182\/blood.V112.11.181.181","volume":"112","author":"G Rosti","year":"2008","unstructured":"Rosti, G. et al. High and early rates of cytogenetic and molecular response with nilotinib 800 mg daily as first line treatment of Ph-positive chronic myeloid leukemia in chronic phase: results of a phase 2 trial of the GIMEMA CML Working Party [abstract]. Blood 112, 181 (2008).","journal-title":"Blood"},{"key":"BFnrclinonc2009112_CR25","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1182\/blood.V112.11.182.182","volume":"112","author":"J Cortes","year":"2008","unstructured":"Cortes, J. et al. Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP) [abstract]. Blood 112, 182 (2008).","journal-title":"Blood"},{"key":"BFnrclinonc2009112_CR26","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1182\/blood.V112.11.446.446","volume":"112","author":"J Cortes","year":"2008","unstructured":"Cortes, J. et al. Efficacy of nilotinib (formerly AMN107) in patients (pts) with newly diagnosed, previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP) [abstract]. Blood 112, 446 (2008).","journal-title":"Blood"},{"key":"BFnrclinonc2009112_CR27","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/sj.leu.2403724","volume":"19","author":"MS Holtz","year":"2005","unstructured":"Holtz, M. S., Forman, S. J. & Bhatia, R. Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli. Leukemia 19, 1034\u20131041 (2005).","journal-title":"Leukemia"},{"key":"BFnrclinonc2009112_CR28","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.1182\/blood.V99.10.3792","volume":"99","author":"MS Holtz","year":"2002","unstructured":"Holtz, M. S. et al. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 99, 3792\u20133800 (2002).","journal-title":"Blood"},{"key":"BFnrclinonc2009112_CR29","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood.V99.1.319","volume":"99","author":"SM Graham","year":"2002","unstructured":"Graham, S. M. et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99, 319\u2013325 (2002).","journal-title":"Blood"},{"key":"BFnrclinonc2009112_CR30","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","volume":"109","author":"P Rousselot","year":"2007","unstructured":"Rousselot, P. et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109, 58\u201360 (2007).","journal-title":"Blood"},{"key":"BFnrclinonc2009112_CR31","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1182\/blood.V112.11.187.187","volume":"112","author":"F Mahon","year":"2008","unstructured":"Mahon, F. et al. Is it possible to stop imatinib in patients with chronic myeloid leukemia? An update from a French pilot study and first results from the multicentre 'Stop Imatinib' (STIM) study [abstract]. Blood 112, 187 (2008).","journal-title":"Blood"},{"key":"BFnrclinonc2009112_CR32","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1080\/10428190802043903","volume":"49","author":"D Verma","year":"2008","unstructured":"Verma, D., Kantarjian, H., Jain, N. & Cortes, J. Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha. Leuk. Lymphoma 49, 1399\u20131402 (2008).","journal-title":"Leuk. Lymphoma"},{"key":"BFnrclinonc2009112_CR33","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1182\/blood-2007-09-112573","volume":"111","author":"M Copland","year":"2008","unstructured":"Copland, M. et al. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood 111, 2843\u20132853 (2008).","journal-title":"Blood"},{"key":"BFnrclinonc2009112_CR34","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1182\/blood.V110.11.1031.1031","volume":"110","author":"A Strauss","year":"2007","unstructured":"Strauss, A. et al. Effective induction of apoptosis in chronic myeloid leukemia CD34+ cells by the histone deacetylase inhibitor LAQ824 in combination with imatinib [abstract]. Blood 110, 1031 (2007).","journal-title":"Blood"},{"key":"BFnrclinonc2009112_CR35","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/nature07016","volume":"453","author":"K Ito","year":"2008","unstructured":"Ito, K. et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature 453, 1072\u20131078 (2008).","journal-title":"Nature"},{"key":"BFnrclinonc2009112_CR36","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/nature07737","volume":"458","author":"C Zhao","year":"2009","unstructured":"Zhao, C. et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 458, 776\u2013779 (2009).","journal-title":"Nature"},{"key":"BFnrclinonc2009112_CR37","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","volume":"108","author":"HA Bradeen","year":"2006","unstructured":"Bradeen, H. A. et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 108, 2332\u20132338 (2006).","journal-title":"Blood"},{"key":"BFnrclinonc2009112_CR38","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/nrd2324","volume":"6","author":"A Quintas-Cardama","year":"2007","unstructured":"Quintas-Cardama, A., Kantarjian, H. & Cortes, J. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat. Rev. Drug Discov. 6, 834\u2013848 (2007).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFnrclinonc2009112_CR39","doi-asserted-by":"publisher","first-page":"11011","DOI":"10.1073\/pnas.0504952102","volume":"102","author":"TA Carter","year":"2005","unstructured":"Carter, T. A. et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc. Natl Acad. Sci. USA 102, 11011\u201311016 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrclinonc2009112_CR40","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1182\/blood.V112.11.3232.3232","volume":"112","author":"J Cortes","year":"2008","unstructured":"Cortes, J. et al. Preliminary clinical activity in a phase I trial of the BCR-ABL\/IGF-1R\/aurora kinase inhibitor XL228 in patients with Ph+ leukemias with either failure to multiple TKI therapies or with T315I mutation [abstract]. Blood 112, 3232 (2008).","journal-title":"Blood"},{"key":"BFnrclinonc2009112_CR41","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1182\/blood.V110.11.1030.1030","volume":"110","author":"R Paquette","year":"2007","unstructured":"Paquette, R. et al. PHA-739358, an aurora kinase inhibitor, induces clinical responses in chronic myeloid leukemia harboring T315I mutations of BCR-ABL. Blood 110, 1030 (2007).","journal-title":"Blood"},{"key":"BFnrclinonc2009112_CR42","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1182\/blood-2007-07-098996","volume":"112","author":"RA Van Etten","year":"2008","unstructured":"Van Etten, R. A. et al. Switch pocket inhibitors of the ABL tyrosine kinase: distinct kinome inhibition profiles and in vivo efficacy in mouse models of CML and B-lymphoblastic leukemia induced by BCR-ABL T315I [abstract]. Blood 112, 576 (2008).","journal-title":"Blood"},{"key":"BFnrclinonc2009112_CR43","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/1097-0142(20010915)92:6<1591::AID-CNCR1485>3.0.CO;2-U","volume":"92","author":"HM Kantarjian","year":"2001","unstructured":"Kantarjian, H. M. et al. Homoharringtonine: history, current research, and future direction. Cancer 92, 1591\u20131605 (2001).","journal-title":"Cancer"},{"key":"BFnrclinonc2009112_CR44","doi-asserted-by":"publisher","first-page":"3516","DOI":"10.1073\/pnas.90.8.3516","volume":"90","author":"KM Kozopas","year":"1993","unstructured":"Kozopas, K. M., Yang, T., Buchan, H. L., Zhou, P. & Craig, R. W. MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc. Natl Acad. Sci. USA 90, 3516\u20133520 (1993).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrclinonc2009112_CR45","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1158\/1535-7163.MCT-05-0164","volume":"5","author":"R Tang","year":"2006","unstructured":"Tang, R. et al. Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells. Mol. Cancer Ther. 5, 723\u2013731 (2006).","journal-title":"Mol. Cancer Ther."},{"key":"BFnrclinonc2009112_CR46","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood.V110.11.2912.2912","volume":"110","author":"Y Chen","year":"2007","unstructured":"Chen, Y. et al. Inhibitory effects of homoharringtonine on leukemic stem cells and BCR-ABL induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice [abstract]. Blood 110, 2912 (2007).","journal-title":"Blood"},{"key":"BFnrclinonc2009112_CR47","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1182\/blood.V112.11.3239.3239","volume":"112","author":"J Cortes","year":"2008","unstructured":"Cortes, J. et al. Safety and efficacy of subcutaneous (SC) omacetaxine mepesuccinate in imatinib(IM)-resistant chronic myeloid leukemia (CML) patients (pts) with the T315I mutation\u2014results of an ongoing multicenter phase II study [abstract]. Blood 112, 3239 (2008).","journal-title":"Blood"},{"key":"BFnrclinonc2009112_CR48","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/leu.2008.84","volume":"22","author":"A Hochhaus","year":"2008","unstructured":"Hochhaus, A. et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 22, 1200\u20131206 (2008).","journal-title":"Leukemia"},{"key":"BFnrclinonc2009112_CR49","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","volume":"109","author":"F Guilhot","year":"2007","unstructured":"Guilhot, F. et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 109, 4143\u20134150 (2007).","journal-title":"Blood"},{"key":"BFnrclinonc2009112_CR50","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1038\/leu.2008.221","volume":"22","author":"J Cortes","year":"2008","unstructured":"Cortes, J. et al. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 22, 2176\u20132183 (2008).","journal-title":"Leukemia"},{"key":"BFnrclinonc2009112_CR51","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1182\/blood.V112.11.3238.3238","volume":"112","author":"H Kantarjian","year":"2008","unstructured":"Kantarjian, H. et al. Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 study [abstract]. Blood 112, 3238 (2008).","journal-title":"Blood"},{"key":"BFnrclinonc2009112_CR52","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1182\/blood.V112.11.3229.3229","volume":"112","author":"P Le Coutre","year":"2008","unstructured":"Le Coutre, P. et al. Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 study [abstract]. Blood 112, 3229 (2008).","journal-title":"Blood"},{"key":"BFnrclinonc2009112_CR53","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1182\/blood-2006-12-061283","volume":"110","author":"F Giles","year":"2007","unstructured":"Giles, F. et al. Nilotinib (Tasigna) in pts with Ph+ CML-BC who are resistant or intolerant to imatinib [abstract]. Blood 110, 1025 (2007).","journal-title":"Blood"},{"key":"BFnrclinonc2009112_CR54","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1182\/blood.V112.11.1098.1098","volume":"112","author":"J Cortes","year":"2008","unstructured":"Cortes, J. et al. Efficacy and safety of bosutinib (SKI-606) in patients with chronic phase (CP) Ph+ chronic myelogenous leukemia (CML) with resistance or intolerance to imatinib [abstract]. Blood 112, 1098 (2008).","journal-title":"Blood"},{"key":"BFnrclinonc2009112_CR55","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1182\/blood-2008-04-152959","volume":"112","author":"C Gambacorti-Passerini","year":"2008","unstructured":"Gambacorti-Passerini, C. et al. Bosutinib (SKI-606) demonstrates clinical activity and is well tolerated in patients with AP and BP CML and Ph+ ALL [abstract]. Blood 112, 1101 (2008).","journal-title":"Blood"}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2009.112.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2009.112","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2009.112.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:02:11Z","timestamp":1684468931000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrclinonc.2009.112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,4]]},"references-count":55,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["BFnrclinonc2009112"],"URL":"https:\/\/doi.org\/10.1038\/nrclinonc.2009.112","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,4]]}}}